BGLC — BioNexus Gene Lab Corp

Nasdaq · Health Care · Health Care Providers & Services · CIK 1737523 ·
Last close
$2.07
Market Cap
$5.00M
52W High
$2.73
52W Low
$1.95
ADV30
5,482
Next earnings
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 22,842 -790 -571,433 -543,575 9,040,130 3,964,962 946,877
Dec 2025 483,760 -3,983 -1,032,000 -1,036,117 9,252,784 4,039,705 637,856
Sep 2025 2,543,823 377,685 -810,269 -708,991 7,621,228 1,153,121 804,966
Jun 2025 2,260,253 368,022 -699,993 -616,172 9,421,205 814,179 1,899,168

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,838,382
Investing CF
$944,751
Financing CF
$298,841
CapEx
$-36,971
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-1.84
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-6,427,227
Inventory
$676,703
Receivables
$648,997
ST Investments
$1,741,532
EBIT TTM
$-2,965,065
Pretax Income TTM
$-2,984,607
Interest Exp TTM
$19,542
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,310,678
EBITDA
$-2,961,790
Free Cash Flow
$-170,052
Enterprise Value
$1,252,549
Total Cash
$3,964,962
Total Debt
$346,624
Shares Out
2,417,314
Trailing EPS
$-1.49
Book Value
$3.35
ROE
-36.6%
ROA
-20.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 7,424,911 -3,158,450 -2,984,607 9,252,784 637,856 -1,838,382
Dec 2024 9,510,646 -1,956,763 -1,598,342 10,433,848 2,111,044 -2,093,260
Dec 2023 9,770,806 -3,079,624 -2,629,043 11,399,793 1,741,941 -1,822,212
Dec 2022 10,928,707 -291,177 -355,966 8,740,162 2,075,149 551,822

Peers — same industry

TickerNameMarket CapLastDaily %
LUDG LUDWIG ENTERPRISES, INC. $5.04M $0.03
XCRT Xcelerate, Inc. $4.28M $0.01
BRTX BioRestorative Therapies, Inc. $6.36M $0.25
ADVB Advanced Biomed Inc. $6.51M $3.98
HLYK HealthLynked Corp $6.91M $2.35

News headlines (Yahoo Finance, 1h cache)

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
2026-03-11 12:45 · Yahoo
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
2026-02-23 13:30 · Yahoo
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
2026-01-28 14:00 · Yahoo
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
2025-12-03 13:45 · Yahoo
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercializati
2025-12-02 13:05 · Yahoo
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
2025-12-01 13:00 · Yahoo
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
2025-11-12 13:00 · Yahoo
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
2025-11-10 13:00 · Yahoo
Top Midday Gainers
2025-07-30 18:02 · Yahoo
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
2025-07-30 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.